SUBSCRIBE
SUBSCRIBE
Gail Dutton

Gail Dutton

Freelance writer

Gail Dutton is a veteran biopharmaceutical reporter, covering the industry from Washington state. You can contact her at gaildutton@gmail.com and see more of her work on Muckrack.

Gregory D. Grove/Courtesy of Neal Gerber Eisenberg
Deals
Proposed SEC Regs Burst SPACs’ Bubble, Signaling Investors’ Return to Quality
SPACs – special purpose acquisition companies – have lost their luster and may never regain it. BioSpace spoke with Neal Gerber Eisenberg’s Gregory D. Grove.
June 12, 2022
 · 
4 min read
 · 
Gail Dutton
Courtesy of Getty Images
Drug Development
Ensysce’s Novel Opioid Appears Impervious to Abuse
Ensysce Biosciences is developing solutions that make opioids safer, and virtually impossible to abuse. BioSpace spoke with CEO Lynn Kirkpatrick about the company’s novel technology.
June 8, 2022
 · 
4 min read
 · 
Gail Dutton
Maria Whitman_ZS Associates
Looming Patent Cliff will be Pharma’s Moment of Truth
In the next eight years, more than 190 drugs will go off-patent for these companies. Of those, 69 are blockbuster drugs. ZS Associates’ Maria Whitman provides analyses and tips.
June 5, 2022
 · 
6 min read
 · 
Gail Dutton
Numinus Co-founder and CEO Payton Nyquvest/Courtes
Drug Development
Numinus CEO: Psychedelic-assisted Psychotherapy Still Driven by Perceptions
BioSpace spoke with Payton Nyquvest, co-founder and CEO of Numinus about changing perceptions around psychedelic-assisted psychotherapy and the company’s work in this space.
June 2, 2022
 · 
6 min read
 · 
Gail Dutton
Drug Development
Invectys is Pioneering HLA-G Immune Checkpoint Inhibitors in Cancer Therapeutics
Invectys is one of only a few companies investigating HLA-G, a natural immune checkpoint inhibitor, for solid tumors.
May 25, 2022
 · 
4 min read
 · 
Gail Dutton
Mammoth Biosciences Co-Founder and CEO Trevor Mart
Business
From Bench to Boardroom, PhD-Wielding Founders Buck Tradition
Today, scientist-founders are likely to remain in charge, shepherding the companies they founded to the next iteration. BioSpace spoke with one such founder, Mammoth Biosciences’ Trevor Martin.
May 25, 2022
 · 
4 min read
 · 
Gail Dutton
Drug Development
New Alzheimer’s Blood Test Supports Early Diagnosis & Patient Selection
A blood test to diagnose Alzheimer’s disease launched in April by Quest Diagnostics has the potential to screen patients for risk years before symptoms appear.
May 24, 2022
 · 
4 min read
 · 
Gail Dutton
Spruce CEO Javier Szwarcberg, and cover photo, cou
Drug Development
Spruce Biosciences Aims to Break Through in CAH, PCOS
Spruce Biosciences is developing what could be the first new therapy treating congenital adrenal hyperplasia (CAH) since the 1960s, and a new therapy for women with polycystic ovary syndrome.
May 18, 2022
 · 
4 min read
 · 
Gail Dutton
Photo: POC Manufacturing/Courtesy of Orgenesis
Industrializing Autologous Cell and Gene Therapy Manufacturing to Bring Quality Products to Patients
Orgenesis is developing a point-of-care manufacturing platform for cell and gene and other advanced therapies to make them more widely available and significantly more affordable.
May 18, 2022
 · 
4 min read
 · 
Gail Dutton
Drug Development
ShouTi’s Rationally Designed Small Molecules are Challenging Biologics and Peptides
ShouTi believes many targets addressed by biologic and peptide therapeutics can be reached by innovative, rationally-designed, best-in-class small molecules that don’t need refrigeration or injection.
May 17, 2022
 · 
4 min read
 · 
Gail Dutton
Alto Neuroscience COO Mikael Eliasson, M.D., Ph.D.
Business
At Alto, New COO Mikael Eliasson Aims to Transform Psychiatry
During the past several years, data generation, data mining and analytics have progressed to the point that it is now possible to bring precision medicine to psychiatry.
May 17, 2022
 · 
6 min read
 · 
Gail Dutton
Policy
Will Proposed COVID-19 TRIPS Waiver Help Patients or Harm Innovation?
The changes are unlikely to help people in developing countries but could reduce innovation among biopharma companies and ultimately do more harm than good.
May 15, 2022
 · 
5 min read
 · 
Gail Dutton
Matthew Clifford_courtesy IDBS
Design Your Digital Strategy Early to Avoid Biotech’s Newest Bottleneck
With data siloed with various researchers and departments, it is broadly inaccessible and eventually forgotten. Digital management has become the new bottleneck in biotech development.
May 14, 2022
 · 
4 min read
 · 
Gail Dutton
Corey Casper and the development of AAHI's bivalen
Drug Development
More Durable, Broader Spectrum Boosters Needed Against COVID-19
Current COVID-19 booster shots have a problem: they last only about four months and appear to have limited efficacy in a vaccinated population. Clearly, a more durable approach is needed.
May 10, 2022
 · 
4 min read
 · 
Gail Dutton
Drug Development
OncoResponse IDs Elite Cancer Responders’ Antibodies to Make IO More Effective
OncoResponse is developing an innovative cancer therapy based upon antibodies produced by patients to components in the tumor microenvironment that regulate the immune response.
May 9, 2022
 · 
4 min read
 · 
Gail Dutton
Load More